Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Open Access
- 19 August 1998
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 90 (16) , 1205-1211
- https://doi.org/10.1093/jnci/90.16.1205
Abstract
Background: Both total dose and dose intensity of adjuvant chemotherapy are postulated to be important variables in the outcome for patients with operable breast cancer. The Cancer and Leukemia Group B study 8541 examined the effects of adjuvant treatment using conventional-range dose and dose intensity in female patients with stage II (axillary lymph node-positive) breast cancer. Methods: Within 6 weeks of surgery (radical mastectomy, modified radical mastectomy, or lumpectomy), 1550 patients with unilateral breast cancer were randomly assigned to one of three treatment arms: high-, moderate-, or low-dose intensity. The patients received cyclophosphamide, doxorubicin, and 5- fluorouracil on day 1 of each chemotherapy cycle, with 5- fluorouracil administration repeated on day 8. The highdose arm had twice the dose intensity and twice the drug dose as the low-dose arm. The moderate-dose arm had two thirds the dose intensity as the high-dose arm but the same total drug dose. Disease-free survival and overall survival were primary end points of the study. Results: At a median follow-up of 9 years, disease-free survival and overall survival for patients on the moderate- and high-dose arms are superior to the corresponding survival measures for patients on the low-dose arm (two-sided P<.0001 and two-sided P = .004, respectively), with no difference in disease-free or overall survival between the moderate- and the high-dose arms. At 5 years, overall survival (average ± standard error) is 79% ± 2% for patients on the high-dose arm, 77% ± 2% for the patients on the moderate-dose arm, and 72% ± 2% for patients on the low-dose arm; disease-free survival is 66% ± 2%, 61% ± 2%, and 56% ± 2%, respectively. Conclusion: Within the conventional dose range for this chemotherapy regimen, a higher dose is associated with better disease-free survival and overall survival. [J Natl Cancer Inst 1998;90: 1205–11]Keywords
This publication has 21 references indexed in Scilit:
- Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.Journal of Clinical Oncology, 1996
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJNCI Journal of the National Cancer Institute, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Pathologic findings from the national surgical adjuvant breast project protocol B-06 10-year pathologic and clinical prognostic discriminantsCancer, 1993
- A Feasibility Study of Intensive CAF as Outpatient Adjuvant Therapy for Stage II Breast Cancer in a Cooperative Group: CALGB 8443Cancer Investigation, 1990
- A suggested follow-up time for breast cancer patientsBritish Journal of Cancer, 1986
- Alkylating agent resistance: in vitro studies with human cell lines.Proceedings of the National Academy of Sciences, 1985
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958